# Shanghai Mediumbank Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-mediumbank-biotechnology-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.mediumbank.net
- Total disclosed funding: $16M
- Latest round: Series B (Apr 15, 2022)
- Investors on record: 2

## About

Based in Shanghai, China, and established in 2019, Shanghai Mediumbank Biotechnology Co., Ltd. is a biotech company that engages in the research and development, production, and sale of cell culture medium. The company's customers cover a variety of biomedical companies, such as monoclonal antibodies, fusion proteins, vaccines, IVDs, etc. In 2021, the company established the first phase production base that has been put into production and is establishing the second phase production base in 2022. And the company's products has passed the quality management certification, ISO13485.

The company developed six cell culture mediums, including CHO cells culture medium, hybridoma and myeloma cells culture medium, HEK293 cells culture medium, insect cells culture medium, virus vaccine cells culture medium, and T cells and stem cells culture medium. Those products can be applied to biological drug research and development, clinical applications and commodities chemical production and other stages. The company also provides solutions, including standard products, culture mediums optimization and development, process optimization, serum-free suspension acclimation, and medium supernatant analysis.

The company plans to use the series B funding to continue R&D products, upgrade the production management quality systems, and establish production bases.

## Funding rounds

- Series B, Apr 15, 2022, $16M — Neovision Capital, Ruiying Capital

## Investors

- Neovision Capital (https://capitalatlas.ai/funds/neovision-capital) — Series B
- Ruiying Capital (https://capitalatlas.ai/funds/ruiying-capital) — Series B